GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Clinical Trials
3.8k
Trial Phases
5 Phases
Drug Approvals
126
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- 5
- 13
- Next
Clinical Trials
Distribution across different clinical trial phases (3334 trials with phase data)β’ Click on a phase to view related trials
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
- Conditions
- Gastrointestinal Neoplasms
- Interventions
- First Posted Date
- 2025-10-21
- Last Posted Date
- 2025-10-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 450
- Registration Number
- NCT07218926
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2025-10-15
- Last Posted Date
- 2025-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT07217119
- Locations
- πΈπͺ
GSK Investigational Site, Stockholm, Sweden
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2025-10-15
- Last Posted Date
- 2025-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT07217184
- Locations
- πΈπͺ
GSK Investigational Site, Falun, Sweden
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
- Conditions
- Neoplasms, Colorectal
- Interventions
- Drug: GSK5460025
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 47
- Registration Number
- NCT07213609
A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above
- Conditions
- Influenza, Human
- Interventions
- Biological: Flu mRNA (Formulation B1)Biological: Flu mRNA (Formulation B3)Biological: Flu mRNA(Formulation A)Combination Product: Comparator 1Combination Product: Comparator 2Combination Product: Comparator 3
- First Posted Date
- 2025-10-03
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 960
- Registration Number
- NCT07204964
- Prev
- 1
- 2
- 3
- 4
- 5
- 713
- Next
News
Alector's Latozinemab Fails Phase III Trial for Frontotemporal Dementia, Company Cuts Workforce by Half
Alector's investigational antibody latozinemab failed to slow disease progression in a 96-week Phase III trial for frontotemporal dementia caused by progranulin gene mutations.
Dovato Demonstrates Non-Inferior Efficacy to Biktarvy with Significantly Less Weight Gain in 96-Week HIV Treatment Study
ViiV Healthcare's PASO DOBLE trial shows Dovato (DTG/3TC) maintains viral suppression as effectively as Biktarvy (BIC/FTC/TAF) at 96 weeks in 553 virologically suppressed HIV-1 patients.
NICE Approves Long-Acting HIV Prevention Injection for England and Wales
The National Institute for Health and Care Excellence (NICE) has recommended cabotegravir long-acting injection for HIV prevention in England and Wales, offering an alternative to daily oral PrEP for high-risk individuals who cannot take oral medications.
Activist Investor Shah Capital Calls for Novavax Sale Amid COVID Vaccine Market Share Struggles
Shah Capital, Novavax's second-largest shareholder with a 7.2% stake, has urged the company's board to pursue a sale, citing three consecutive years of poor COVID-19 vaccine performance.
Clover Biopharmaceuticals Reports Positive Phase I Data for First-in-Class RSV-hMPV-PIV3 Combination Vaccines
Clover's combination vaccines SCB-1022 and SCB-1033 demonstrated robust immune responses with 6-8 fold increases in RSV neutralizing antibodies, 6-9 fold increases for hMPV, and 4 fold increases for PIV3 in older adults.
New Report Analyzes 1,775 Clinical-Stage Pharma Partnerships from 2020-2025
ResearchAndMarkets.com released a comprehensive report analyzing 1,775 clinical-stage partnering deals in pharma and biotech from 2020-2025, providing detailed financial terms and strategic insights.
GC Biopharma Partners with Curevo Vaccine to Manufacture Next-Generation Shingles Vaccine with Improved Tolerability
GC Biopharma has secured contract manufacturing rights for amezosvatein (CRV-101), a recombinant shingles vaccine designed to reduce injection-site pain and systemic reactions compared to current market leader Shingrix.
Bioxodes Appoints Industry Veteran Philippe Monteyne as Chairman to Advance Breakthrough Stroke Therapy BIOX-101
Bioxodes has appointed Philippe Monteyne, MD, PhD, a former GSK and Sanofi executive with extensive neurological expertise, as chairman of its Board of Directors to guide development of breakthrough stroke candidate BIOX-101.
Sitryx Receives FDA Clearance for First-in-Class PKM2 Modulator SYX-5219 in Atopic Dermatitis
Sitryx Therapeutics received FDA clearance for its IND application for SYX-5219, a first-in-class oral PKM2 modulator targeting atopic dermatitis.
AnaptysBio Plans Corporate Split to Separate Royalty Assets from Drug Development Operations
AnaptysBio announced plans to separate into two independent public companies by year-end 2026, creating distinct investment opportunities for royalty management and drug development operations.